Biblio
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023:JCO2201794.
A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023.
Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. bioRxiv. 2023.
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022.
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. Leuk Lymphoma. 2022:1-5.
. . .
CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Exp Hematol. 2019.
. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Rep. 2019;27(1):238-254.e6.
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019.
. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2019;35(2):333-335.
Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326-4335.
. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018;34(5):724-740.e4.